• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aspire Biopharma Holdings, Inc. - Common Stock (NQ:ASBP)

    2.155 +2.105 (+4210.00%)
    Streaming Delayed Price Updated: 3:41 PM EST, Jan 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aspire Biopharma Holdings, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    Aspire Biopharma Announces Reverse Stock Split
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
    Via ACCESS Newswire
    News headline image
    Brookmount Gold (OTC: BMXI) Profitable Q3 2025, Gold Production, Spinoff Dividends Takes Shape – More Stocks Inside
    Via AB Newswire
    News headline image
    Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Provides Q3 2025 Business Update
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
    Via ACCESS Newswire
    News headline image
    Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
    Via ACCESS Newswire
    News headline image
    TOMI Environmental (NASDAQ: TOMZ) Expands SteraMist – Protecting People from Germs, Viruses & Biohazards | More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
    Via ACCESS Newswire
    News headline image
    Sidoti Events, LLC's Virtual August Micro-Cap Conference
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc. Announces CEO Transition
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
    Via ACCESS Newswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.